Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of chronic hepatitis B or C on pharmacokinetics of cholyl-lysyl-fluorescein (NRL972)
2008-003547-36Phase 2Completed
- Sponsor
- Norgine
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorescein lisicol in Chronic Hepatitis B (CHB), hepatitis C virus infection, Cirrhosis and 1 more, sponsored by Norgine. Primary endpoint: Primary pharmacokinetic endpoints. Started Feb 2009; status: completed.
02
Drugs
fluorescein lisicol
03
Conditions
Chronic Hepatitis B (CHB)hepatitis C virus infectionCirrhosishepatic dysfunction
Beyond the preview
Go deeper on 2008-003547-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003547-36.